2025-10-30 - Analysis Report
Okay, here's a comprehensive analysis of Teladoc Health Inc. (TDOC) based on the provided data.  I will present the data with brief commentary, followed by an overall assessment.

**1. Performance vs. S&P 500 (VOO)**

*   **Headline Numbers:**
    *   TDOC Cumulative Return: -58.94%
    *   VOO Cumulative Return: 105.08%
    *   Absolute Divergence: -158.6%
    *   Relative Divergence: 0.9
*   **Company Overview:** Teladoc Health Inc. is a telehealth company offering virtual healthcare services.

*   **Analysis:** TDOC has significantly underperformed the S&P 500, with a substantial negative divergence. The relative divergence of 0.9 indicates the stock is near its historical low relative to the S&P 500.

*   **Alpha/Beta Analysis (Selected Periods):**

    | Year       | CAGR      | MDD     | Alpha     | Beta   | Cap(B) |
    | ---------- | --------- | ------- | --------- | ------ | ------ |
    | 2015-2017  | 77.0%     | 70.4%   | 51.0%     | -0.1   | 6.2    |
    | 2018-2020  | 105.0%    | 80.9%   | 81.0%     | 0.3    | 35.4   |
    | 2021-2023  | -315.0%   | 85.9%   | -316.0%   | -1.8   | 3.8    |
    | 2023-2025  | -30.0%    | 81.6%   | -98.0%    | -0.8   | 1.5    |

    *   **Analysis:**
        *   **Early Growth (2015-2020):** Strong CAGR and positive Alpha suggest outperformance during the earlier periods. High volatility, as evidenced by the large MDD figures.
        *   **Recent Struggles (2021-2025):** Very negative CAGR and Alpha signify severe underperformance in recent years. Negative Beta indicates an inverse correlation with the market.
        *   **Decreasing Market Cap:** The market capitalization has decreased significantly, reflecting investor concerns.

**2. Recent Price Action**

*   **Key Numbers:**
    *   Current Price: $8.535
    *   Previous Close: $8.36
    *   Change: +2.09%
    *   5-day Moving Average: $8.789
    *   20-day Moving Average: $8.6337
    *   60-day Moving Average: $7.967

*   **Analysis:** The stock is trading below its 5-day and 20-day moving averages but above the 60-day moving average, suggesting a possible short-term downtrend and a potential long-term uptrend. The recent price increase of 2.09% suggests a possible short-term bullish signal.

**3. Market Risk Indicators & Expected Return**

*   **Key Numbers:**
    *   Market Risk Indicator (MRI): 0.9 (Medium Investment)
    *   RSI: 45.16
    *   PPO: -0.14
    *   Hybrid Signal: Cash 0%, Buy 100% (Very Safe - MRI: 0.9)
    *   Recent (20-day) Relative Divergence Change: -0.8 (Short-term decline)
    *   Expected Return: -9657.8%

*   **Analysis:**

    *   **MRI:** A MRI of 0.9 suggests a medium investment is recommended.
    *   **RSI:** An RSI of 45.16 is neutral, not indicating overbought or oversold conditions.
    *   **PPO:** A PPO of -0.14 suggests that the short-term moving average is slightly below the long-term moving average, indicating a potential downtrend.
    *   **Hybrid Signal:** The hybrid signal indicates a "Buy" recommendation with 100% allocation, labeled as "Very Safe" due to the MRI score.
    *   **Divergence Change:** The recent decline in relative divergence suggests further short-term underperformance compared to the S&P 500.
    *   **Expected Return:** The extremely negative expected return is highly concerning, indicating significant anticipated underperformance compared to the S&P 500 over the long term if a lump sum is invested now. *Important Note:*  This extremely large negative number likely represents an artifact of the model used to calculate this projection given recent extreme underperformance.
    *   **Price Change Impact:** The recent price increase of 2.09% suggests a short-term bullish signal, which might be a reaction to recent news or could be a temporary fluctuation.

**4. Recent News & Significant Events**

*   **Key Headlines:**

    *   Executive Changes: Mala Murthy appointed as CFO of TriNet Group.
    *   Earnings Preview: Articles discussing expectations for Teladoc's Q3 earnings.
    *   Stock Performance: Article highlighting a 10% surge in Teladoc's stock price.
    *   GeneDx Earnings: News about GeneDx Holdings Corp. surpassing estimates.

*   **Analysis:** The news is a mixed bag. The CFO announcement is unrelated to Teladoc. The earnings preview articles indicate market attention on the upcoming Q3 results. The report of a 10% surge is positive but needs to be considered in the context of the company's overall poor performance.

**4-2. Analyst Opinions**

*   **Key Figures:**

    *   Consensus: Hold
    *   Mean Rating: 2.64 (Hold)
    *   Number of Opinions: 20
    *   Target Price (Avg/High/Low): $9.25 / $12.00 / $7.00

*   **Analysis:** Analyst consensus is "Hold" with a mean rating reflecting a neutral stance. The average target price of $9.25 suggests a moderate upside from the current price, but the range is wide, indicating uncertainty. The absence of recent rating changes suggests no significant shifts in analyst sentiment.

**5. Recent Earnings Analysis**

| 날짜         | EPS    | 매출      |
| ------------ | ------ | --------- |
| 2025-07-30   | -0.19  | 0.63 B$   |
| 2025-05-01   | -0.53  | 0.63 B$   |
| 2024-10-31   | -0.19  | 0.64 B$   |
| 2024-08-01   | -4.92  | 0.64 B$   |
| 2025-07-30   | -4.92  | 0.64 B$   |

*   **Analysis:** Teladoc has consistently reported negative EPS, with a significant loss in Q3 2024. Revenue has remained relatively stable around $0.63-0.64 billion per quarter.

**6. Financial Information: Revenue and Profitability**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | ------------- |
| 2025-06-30   | $0.63B    | 69.85%        |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |
| 2024-06-30   | $0.64B    | 70.73%        |

**Capital and Profitability**

| Quarter      | Equity   | ROE       |
| ------------ | -------- | --------- |
| 2025-06-30   | $1.42B   | -2.30%    |
| 2025-03-31   | $1.43B   | -6.52%    |
| 2024-12-31   | $1.49B   | -3.25%    |
| 2024-09-30   | $1.51B   | -2.21%    |
| 2024-06-30   | $1.50B   | -55.77%   |

*   **Analysis:** While revenue has been steady, the company struggles with profitability, as evidenced by the negative ROE values. The large negative ROE in Q2 2024 is particularly concerning.

**7. Overall Assessment**

Teladoc Health Inc. (TDOC) presents a mixed picture.

*   **Negative Factors:**

    *   **Significant Underperformance:** The stock has dramatically underperformed the S&P 500.
    *   **Consistent Losses:** The company has consistently reported negative EPS and ROE, indicating profitability issues.
    *   **Negative Expected Return:** The projected negative return suggests a high risk of continued underperformance.
    *   **Analyst Sentiment:** While analysts have a "Hold" rating, the overall sentiment is cautious.

*   **Positive Factors:**

    *   **Recent Price Increase:** A recent surge in stock price might indicate a potential short-term rebound.
    *   **MRI:** Medium Risk Investment based on MRI suggests.
    *   **Relatively High Revenues:** The revenues remain constant, suggesting a potential for future growth
    *   **Hybrid Signal:** The hybrid signal is indicating a "Buy" with 100% cash allocation.

*   **Conclusion:**

    Based on the available data, investing in TDOC appears highly risky. The company's persistent losses, underperformance relative to the market, and negative expected return are significant red flags. While there are some positive indicators, such as a recent price increase and a "Hold" analyst rating, these are not sufficient to outweigh the negative factors. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in TDOC.
